Palisade Bio director reports RSU grant and vesting

Palisade Bio director Donald Allen Williams increased his equity stake through stock-based compensation rather than market trades.

Rhea-AI Filing Summary

Palisade Bio director Donald Allen Williams increased his equity stake through stock-based compensation rather than market trades. He received a grant of 1,498,900 restricted stock units (RSUs) that vest in three equal annual installments starting on the earlier of the 2027 annual stockholders meeting or the anniversary of June 10, 2026, subject to continued service. On June 10, 2026, 60,666 previously granted RSUs vested and were converted into Common Stock at no cash exercise price, contributing to direct ownership of 1,509,628 common shares and 121,334 remaining RSUs. He also has 3,000 additional shares held indirectly through his defined benefit plan.

Insights

Equity compensation analyst

Transactions reflect routine equity compensation grants and RSU vesting, not open‑market buying or selling.

Director Donald Allen Williams received a grant of 1,498,900 RSUs and had 60,666 RSUs vest into Common Stock on June 10, 2026. Both are non-cash compensation events at a stated price of $0.0000 per share, typical for stock awards.

The filing shows 1,509,628 Common Stock shares held directly after these transactions, plus 121,334 remaining RSUs and 3,000 shares indirectly via a defined benefit plan. Because there are no open‑market purchases or sales, these actions mainly adjust the mix and scale of his equity-based compensation rather than signaling a change in market view.

Insider Trade Summary

60,666 shares exercised/converted

Exercise 4 txns

Insider Williams Donald Allen

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	60,666	$0.00	$0.00
Grant/Award	Common Stock	1,498,900	$0.00	$0.00
Exercise	Common Stock	60,666	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 121,334 contracts (Direct); Common Stock — 1,570,294 shares (Direct); Common Stock — 3,000 shares (Indirect, By Reporting Person's Defined Benefit Plan)

Footnotes (3)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.
2. F2. The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026.
3. F3. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.

Key Figures

RSU grant: 1,498,900 units RSUs vested and converted: 60,666 units/shares Direct Common Stock holdings: 1,509,628 shares +3 more

6 metrics

RSU grant 1,498,900 units Restricted Stock Units granted to director on June 10, 2026

RSUs vested and converted 60,666 units/shares RSUs vested and converted into Common Stock on June 10, 2026

Direct Common Stock holdings 1,509,628 shares Total Common Stock directly held following reported transactions

Remaining RSU balance 121,334 units Restricted Stock Units remaining after the 60,666-unit vesting event

Indirect holdings 3,000 shares Common Stock held via reporting person’s defined benefit plan

Exercise price for RSU conversion $0.0000 per share Price per share for RSUs converted to Common Stock

Key Terms

Restricted Stock Units, service-based vesting requirement, annual meeting of stockholders, defined benefit plan, +1 more

5 terms

Restricted Stock Units financial

"The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

service-based vesting requirement financial

"The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments..."

annual meeting of stockholders financial

"with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders..."

defined benefit plan financial

"nature_of_ownership: By Reporting Person's Defined Benefit Plan"

A defined benefit plan is a retirement program that guarantees workers a specific monthly payment after they retire, with the employer responsible for funding whatever is needed to meet that promise. Investors care because these plans create long-term payment obligations that can affect a company’s cash flow and balance sheet—similar to a homeowner having a fixed mortgage the household must cover regardless of income swings.

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palisade Bio (PALI) director Donald Allen Williams acquire in this Form 4?

Donald Allen Williams received a grant of 1,498,900 restricted stock units and had 60,666 RSUs vest into Common Stock. These awards are equity compensation, not open‑market purchases, and increase his potential ownership stake in Palisade Bio over time as they vest.

How many Palisade Bio (PALI) shares does Donald Allen Williams hold after these transactions?

After the reported transactions, Donald Allen Williams directly holds 1,509,628 shares of Palisade Bio Common Stock. He also has 121,334 remaining RSUs that may convert into shares as they vest, plus 3,000 additional shares held indirectly via his defined benefit plan.

Were there any open-market stock purchases or sales in this Palisade Bio (PALI) Form 4?

No open‑market purchases or sales are reported. The transactions involve RSU grants, RSU vesting, and related issuance of Common Stock at a zero exercise price, all categorized as acquisitions rather than market trades, making them primarily compensation and accounting events.

How do the new RSU grants for Palisade Bio (PALI) director vest over time?

The newly granted RSUs vest in three equal annual installments. The first installment vests on the earlier of the 2027 annual meeting of stockholders or the anniversary of June 10, 2026, and vesting remains contingent on the director’s continuous service with Palisade Bio.

What happened to the 60,666 RSUs reported in the Palisade Bio (PALI) Form 4?

The 60,666 RSUs vested on June 10, 2026 and were converted into an equal number of Palisade Bio Common Stock shares. This raised Donald Allen Williams’ direct share ownership while reducing his outstanding RSU balance recorded in the derivative section of the filing.

What indirect ownership does Donald Allen Williams have in Palisade Bio (PALI)?

In addition to his direct holdings, Donald Allen Williams has 3,000 shares of Palisade Bio Common Stock held indirectly through his defined benefit plan. This position is reported separately from his directly owned shares as indirect ownership in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 08:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Donald Allen

(Last) (First) (Middle)

C/O PALISADE BIO, INC.

4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A(1)		1,498,900	A	(1)	1,509,628	D
Common Stock	06/10/2026		M(2)		60,666	A	(2)	1,570,294	D
Common Stock								3,000	I	By Reporting Person's Defined Benefit Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	06/10/2026		M			60,666	(3)	(3)	Common Stock	60,666	$0	121,334	D

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.

2. The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026.

3. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.

	/s/ Ryker Willie, Attorney-in-Fact for Donald Allen Williams	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)